The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Top Cited Papers
Open Access
- 9 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (7), 1805-1815
- https://doi.org/10.1038/s41375-020-0891-0
Abstract
A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th, 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by ≥25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958).This publication has 41 references indexed in Scilit:
- Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosisBone Marrow Transplantation, 2020
- Recommendations for the management of hemophagocytic lymphohistiocytosis in adultsBlood, 2019
- Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte SocietyThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Inflammation and myeloproliferative neoplasmsJournal of Autoimmunity, 2017
- Specificity of JAK-kinase inhibition determines impact on human and murine T-cell functionLeukemia, 2015
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyLeukemia, 2015
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuationInternational Journal of Hematology, 2014
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosisLeukemia, 2013
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisThe New England Journal of Medicine, 2012
- Congenital eventration of the left dome of the diaphragm.1982